Home › Monoclonal Gammopathy of Undetermined Significance › New York
Monoclonal Gammopathy of Undetermined Significance clinical trials in New York
3 studies for Monoclonal Gammopathy of Undetermined Significance are looking for participants at sites in New York.
Cities in New York
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06055894A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- NYU Langone Health Perlmutter Cancer Center, New York
- Stony Brook University Hospital, Stony Brook
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT06140524A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT05640843From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.